Comprehensive genomic profiling (CGP) solutions

Leverage the depth and breadth of next-generation sequencing for precision oncology research.

Find your product Contact us
Scientist looking through a scope

Attain deeper insights about solid tumors with CGP

Cancers such as breast cancer, non-small cell lung cancer (NSCLC), and colorectal cancer are complex diseases for which the number of biomarkers and tumor-agnostic treatments are increasing exponentially.1 For precision oncology strategies to be successful, clinicians and researchers must be able to distinguish the actionable genomic alterations in the appropriate disease context.

Comprehensive genomic profiling (CGP) is a next-generation sequencing technology that provides meaningful insights, uncovering the unique molecular signature of each tumor. Unlike single biomarker or hotspot assays, CGP is capable of detecting all four main mutation classes (single nucleotide variants, insertions/deletions, copy number variations, and rearrangements/fusions) known to drive cancer growth across a broad panel of cancer-related genes as well as key complex signatures. 

Technological advances have increased the value of comprehensive genomic profiling to deliver more insights, more quickly, potentially offering significant savings in sample, time, and cost.

Leveraging the FoundationOne® Analysis Platform and the AVENIO workflow, AVENIO Tumor Tissue CGP Kits are part of Roche’s broad oncology portfolio that offers flexible solutions to meet your research needs. With CGP solutions from Roche, you can achieve deeper genomic insights about solid tumors in your own lab, fostering discovery and advancing precision oncology.

Featured products

Find your product

Benefits of comprehensive genomic profiling solutions from Roche

Proven technology

Powered by the expertise and technology of Roche and Foundation Medicine®

The development of high-quality comprehensive genomic profiling assays is technically challenging and requires the integration of deep oncology, technology, and bioinformatics expertise. 

  • Our portfolio of CGP solutions are built on Foundation Medicine’s deep understanding of cancer genomics and its application in clinical practice, supported by Roche’s 125-year legacy of innovation.
  • Roche is a global leader in pharmaceuticals and diagnostics and a pioneer in personalized medicine. We have supported 24 million patients with Roche medicines and delivered 30 billion in vitro diagnostics tests in 2024.2
  • Foundation Medicine has proven expertise in comprehensive genomic profiling, having delivered >1.3 million patient CGP reports and produced 1,000+ peer-reviewed oncology publications.3 In addition, Foundation Medicine send-out solutions have been used in > 500 clinical trials.4
Meaningful insights

Accurate and relevant comprehensive genomic insights

Roche’s comprehensive genomic profiling solutions leverage Foundation Medicine’s proven panel design and evidence-based analytics to deliver high-confidence genomic insights and fewer missed opportunities compared to single-biomarker and hotspot testing.

  • The AVENIO Tumor Tissue CGP Kits offer a comprehensive 335-gene panel. Aligned with the FoundationOne® CDx panel design,5,6,7 the kits detect all four major classes of genomic variants: single-base mutations, insertions/deletions, copy number variations, and rearrangements/fusions and detect complex genomic signatures such as tumor mutational burden (TMB), microsatellite instability (MSI), genomic loss of heterozygosity (gLOH), and homologous recombination deficiency signature (HRDsig).6,7,8

  • AVENIO Tissue Tumor CGP kits include the expertly curated FoundationOne® Analysis Platform, a cloud-based secondary analysis software built on Foundation Medicine’s proprietary evidence-based algorithms.

  • Roche CGP solutions also include compatibility with tertiary analysis softwares such as navify® Mutation Profiler, to provide relevant genomic interpretation with biological significance.9
Efficient workflows

Efficient and streamlined NGS workflows

AVENIO comprehensive genomic profiling (CGP) kits offer both manual and automated workflows, providing streamlined, end-to-end solutions from tissue sample to result generation, ensuring simplicity and efficiency.

  • A fast, highly efficient, and safe xylene-free DNA extraction protocol ensures high DNA yields and quality from challenging formalin-fixed paraffin-embedded (FFPE) samples.6

  • AVENIO CGP workflows employ an enhanced library preparation protocol with a reduced, one-hour ligation time. This, combined with an optimized target enrichment workflow offering increased multiplexing capabilities, leads to lower per-sample sequencing costs.6

  • Roche CGP solutions offer end-to-end, automated data management with the user-friendly AVENIO Connect software (included with the kits). Key features include Human Genome Variation Society (HGVS) annotation, automated data upload and download, and robust customer support.8

  • Both the manual and automated kit workflows enable streamlined, end-to-end workflows, with a less than five-day turnaround time from DNA extraction to result generation.6,7

Contact us

Do you have any questions about Roche products and services? We’re here to help. Fill out the form to have a Roche representative contact you.

This form is provided as a contact service and does not replace the advice of a physician. Roche cannot respond to questions about general medical information or questions regarding your personal medical condition.

Please do not use this form to report complaints or adverse events, or to ask any questions regarding medical products. To report complaints or adverse events, see the information on this page.

Related health topics

The AVENIO Tumor Tissue CGP Kit portfolio is for Research Use Only. Not for use in diagnostic procedures. 

AVENIO Edge reagents and workflows are for Research Use Only when used with the AVENIO Tumor Tissue CGP kit portfolio. Not for use in diagnostic procedures. 

AVENIO Connect Software and FoundationOne Analysis Platform are for Research Use Only. Not for use in diagnostic procedures. The AVENIO Edge System and consumables are not part of the AVENIO Tumor Tissue CGP Automated Kit and should be purchased as a mandatory add-on. 

The AVENIO Connect Software is included in the price of the AVENIO Tumor Tissue CGP Automated Kit. NovaSeq and NextSeq, instruments and associated sequencing reagents, are manufactured and sold by Illumina and are not supplied by Roche.

Tertiary analysis with navify® Mutation Profiler is not part of the AVENIO Tumor Tissue CGP Automated Kit and may be purchased as an optional add-on. 

navify® Mutation Profiler for Research Use Only. Not for use in diagnostic procedures. 

References

  1. Moore D, Guinigundo A. J Adv Pract Oncol. 2023 Apr;14(Suppl 1):15-37.

  2. F. Hoffmann-La Roche Ltd. Investors. [Internet; cited 2025 Aug 16]. Available from: https://www.roche.com/investors.

  3. Foundation Medicine. Products & Services. [Internet; cited 2025 Aug 16]. Available from: https://www.foundationmedicine.com/info/about-our-products-and-services

  4. Foundation Medicine Inc. Data on file.

  5. F. Hoffmann-La Roche. Data on file.

  6. F. Hoffmann-La Roche Ltd. AVENIO Tumor Tissue CGP Kit V2 Instructions for Use v3.0. December 2025.

  7. F. Hoffmann-La Roche Ltd. AVENIO Tumor Tissue CGP Automated Kit IFU v2.0. May 2025.

  8. F. Hoffmann-La Roche Ltd. AVENIO Connect Software User Assistance. (v2.4) December 2025.

  9. navify® Mutation Profiler Instructions for Use. (v2.6). 2024.